ALLO Announces Interim Futility Analysis of ALPHA3 Trial: 58.3% MRD-Negative vs 16.7% Observation, 41.6% Absolute Difference, No CRS/ICANS/GvHD, Outpatient Management, High-Risk LBCL Features
Allogene Therapeutics, Inc. Common Stock · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · Now $2.15
Post-detection moves
1h
—
1d
—
3d
—
7d
—
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS